PHR's earnings-beat streak and wide moat sit against declining estimate revisions, a confirmed technical downtrend, heavy options hedging, and modest insider selling.
Thesis pillars
- Earnings Beat Streak With Wide Moat→Stable
- Deteriorating Estimates And Downtrend↓Deteriorating
- Overbought Bear Rally Momentum↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 31, 2026
Phreesia, Inc. (PHR) Stock Analysis
Healthcare · Health Information Services
Sell if holding. Analyst target reached at $12.44 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3).
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering... Read more
Sell if holding. Analyst target reached at $12.44 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.9/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 35d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-11-02Recent Developments — Phreesia, Inc.
Latest news
- NEWS Transcript : Phreesia, Inc., Q2 2027 Earnings Call, Sep 02, 2026 - marketscreener.com — marketscreener.com neutral
- NEWS Phreesia Q2 Earnings Call Highlights - Yahoo Finance — Yahoo Finance neutral
- NEWS Phreesia Q2 FY2027 slides: revenue up 10%, shares fall on EPS miss - Investing.com India — Investing.com India negative
- NEWS Phreesia Q2 FY2027 slides: revenue up 10%, shares fall on EPS miss - Investing.com Canada — Investing.com Canada negative
- NEWS Phreesia Q2 FY2027 slides: revenue up 10%, shares fall on EPS miss - Investing.com UK — Investing.com UK negative
Generated 2026-11-02T11:43:20Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $12.44 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $11.57. Score 5.9/10, moderate confidence.
Analyst target: $12.54 (+0.8% upside). Prior stop was $11.57. Stop-loss: $11.57.
Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3); Consecutive earnings misses (2).
Phreesia, Inc. trades at a P/E of 73.2 (forward 7.8). TrendMatrix value score: 6.5/10. Verdict: Sell.
22 analysts cover PHR with a consensus score of 3.7/5. Average price target: $14.
What does Phreesia, Inc. do?Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the...
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.